Magle Chemoswed Holding Reports Financial Results For Second Quarter 2025
Magle Group announces its Q2 2025 results amid short-term macroeconomic challenges, highlighting underlying strategic progress despite a temporary setback in financial performance. The quarter was impacted by delayed high-value orders, raw material shortages, and non-recurring integration costs tied to the Group’s recent acquisitions.
Q1 2025 KEY INDICATORS
- Revenues amounted to 52.4 MSEK (46.0)
- EBITDA equaled -20.6 MSEK (5.3)
- Operating profit (EBIT) is -29.0 MSEK (1.3)
- Earnings per share SEK -1.35 (0.01) per share
” While the second quarter did not meet our expectations due to external pressures, these headwinds are temporary. We remain confident in our long-term strategy and continue to see strong demand across our technologies and services. Integration of our newly acquired units Magle Biopolymers and Magle Biopharma, is progressing and will strengthen our market position and capabilities.” says Justin Pierce, CEO